INNATE PHARMA : Appoints Nicolai Wagtmann Chief Scientific Officer
The Company specializes in the development of new monoclonal antibodies targeting receptors and pathways controlling the activation of innate immunity cells. Its innovative approaches have led to licensing agreements with Novo Nordisk A/S and Bristol-Myers Squibb.
Incorporated in 1999 and listed on NYSE-Euronext in Paris in 2006, Innate Pharma is based in Marseilles, France, and had 84 employees as at June 30, 2013.
Learn more about Innate Pharma at www.innate-pharma.com .
Practical Information about Innate Pharma shares:
|Innate Pharma||ATCG Press|
|Laure-Hélène Mercier||Marielle Bricman|
|Director, Investor Relations|
|Phone: +33 (0)4 30 30 30 87||Mob.: +33 (0)6 26 94 18 53|
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts